Softgel Capsules Market is expected to reach US$ 1.9 Billion at a CAGR of 6.0% by 2032 | FMI

 The global Softgel Capsules Market is anticipated to create robust growth opportunities by registering a CAGR of 6.0% from 2022 to 2032. The global market enjoyed a valuation of US$ 1.1 Billion by the end of the year 2022 to surpass a valuation of US$ 1.9 Billion by the year 2032.


According to a recent study by Future Market Insights, gelatin softgel capsules are leading the market with a share of about 75.4% in the year 2021, within the global market. During the historic period, the global softgel capsules exhibited a growth of approximately 3.9% from 2012 to 2021. The market value for softgel capsules was approximately 35.5% of the overall US$ 3.1 Billion global gelatin capsules market in 2021.

To learn more about this report: https://www.futuremarketinsights.com/reports/softgel-capsules-market

The gelatin shells tight shield the material from contamination by the air as well as the outside environment. In addition to visible light, the shell can be designed to block ultraviolet (UV) light. Additionally, softgel capsule formulation improves operator safety by reducing contamination caused by dust handling. Softgel capsules (SGCs) appear more appealing and pleasurable to consumers as they can be produced in a variety of forms, sizes, and colors, as well as diverse drug delivery systems such as chewable softgels and meltable softgels.

Report Highlights

Vegetarian softgel capsules are being produced by a number of different businesses. They comprise pullulan, starch, and HPMC capsules. This is anticipated to lead to increased product personalization in the pharmaceutical, cosmetic, and nutraceutical sectors, which could present profitable opportunities for the producers of softgel capsules.

Attributing to the exact compounding, blending, and dispensing of liquid fill ingredients, it is possible for an API with a better degree of accuracy and more consistency between various production lots. Since the entire encapsulation process can be completed inertly to safeguard pharmaceuticals against oxidation and degradation, soft gelatin capsule products often have superior stability.

Recent Developments

Softgel capsule producers are increasing their product lines to offer a variety of vegan softgel capsules with improved attributes such as faster disintegration, increased gastric acid resistance, enteric coating, and specially developed capsules for clinical studies in order to maximize their revenue.

SGC technology is predicted to be relatively expensive to manufacturers, which is likely to rise consumer prices. Various pharmaceutical businesses lack the specialized equipment necessary to fill SGCs, hence they generally rely on contract laboratories/manufacturers for supplies.

Another upcoming issue with the adoption of soft gelatin capsule products is that some people have dietary restrictions that preclude them from eating animal products contained in SGCs. Gelatin is typically derived from pig and cow bones, skins, and other animal parts. Many vegetarians avoid using capsule shells since they are manufactured from animal tissues

Competitive Landscape

Primary companies participating in the global softgel capsules market are continuing to invest in technologies that provide alternatives to traditional drug delivery systems as the market for softgel products is still in its infancy. However, some businesses continue to only offer hard and soft gelatin capsules in their product offering. If these companies add softgel capsules, vegetarian capsules, and other capsules made from plant-based gelatin to their product line, they can anticipate significant incremental growth prospects.

Aenova began construction of a new structure for highly potent active substances at its Regensburg location in April 2022. Modern manufacturing facilities produce extremely effective pharmaceuticals, particularly those for cancer. Aenova released VegaGels, their most recent vegan soft capsules, in November 2020. They adhere to Chinese, European Union, and American regulatory requirements.

Therefore, the introduction of new technologies to the market, such as the 3D printing of softgel capsules, will be a game-changer, and would further present the global market with lucrative opportunities for expansion.

Key Market Players: 

  • Aenova Group GmbH
  • Fuji Capsule Co., Ltd
  • Sirio Pharma Company Limited
  • Catalent, Inc
  • EuroCaps Ltd
  • Guangdong Yichao Biological Co., Ltd.
  • Elnova Pharma
  • Captek Softgel International Inc
  • Hunan Er-Kang Pharmaceutical Co., Ltd
  • Soft Gel Technologies Inc.
  • Patheon
  • United Labs
  • Curtis Health Caps
  • Delpharm Evreux
  • Procaps Group

Key Market Segments Covered in Softgel Capsules Industry Research

By Product:

  • Gelatin Softgel Capsules
  • Vegetarian Softgel Capsules

By Raw Material:

  • Type-A Gelatin (Pork Skin)
  • Type-B Gelatin (Animal Bones & Skin)
  • Fish Bone Gelatin
  • Cellulose Derivatives
  • Starch Material

By Application:

  • Antacid & Antiflatulent Preparations
  • Antianemic Preparations Hematinic Preparations)
  • Anti-inflammatory Drugs
  • Antibiotic & Antibacterial Drugs
  • Cough & Cold Preparations
  • Cardiovascular Therapy Drugs
  • Health Supplements
  • Vitamin & Dietary Supplements
  • Other Therapeutic Applications

By End User:

  • In-house Manufacturing
    • Pharmaceutical Companies
    • Nutraceutical Companies
    • Cosmeceutical Companies
  • Contract Manufacturing Organizations

By Route of Administration:

  • Oral Softgels
  • Suppositories
  • Pessaries
  • Twist off Softgels
  • Others

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more